Bone infections and bone graft substitutes for local antibiotic therapy.
Fani Lalidou, George Kolios, Georgios I Drosos
https://pubmed.ncbi.nlm.nih.gov/24504740/Actively Recruiting
Led by ASST Ovest Milanese · Updated on 2024-04-29
140
Participants Needed
7
Research Sites
13 weeks
Total Duration
Researchers are evaluating the management of acute and chronic osteomyelitis in patients with diabetic foot syndrome, focusing on infections localized in the forefoot. This prospective multicenter randomized trial compares the effectiveness and safety of a bioactive glass device S53P4 against standard surgical care practices. The goal is to assess healing rates and other outcomes related to bone infection treatment in specialized centers. Participants are randomly assigned to one of two groups. Group A receives surgical removal of the infected bone and soft tissue debridement, along with systemic antibiotics and optional bone substitutes except bioactive glasses. Group B undergoes similar debridement but preserves the bone cortex while replacing infected soft bone with the S53P4 bioactive glass according to its approved use. Both groups aim for primary wound closure and may have vacuum drainage placed postoperatively. Participants are followed closely after surgery with biweekly visits up to three months or until healing, and then at six and twelve months. Assessments include wound evaluation, x-rays, histopathology, laboratory tests, and quality of life and foot function questionnaires. Researchers monitor healing progression, complications such as reinfection, recurrence rates, and functional recovery. The primary outcome is the healing rate at six months, with additional measures including antibiotic duration, re-interventions, amputations, and surgery characteristics.
CONDITIONS
RCT on Bioactive Glass S53P4 in Diabetic Foot Osteomyelitis in the Forefoot (DFORCT)
D
Dr. Roberto De Giglio, Med Doctor
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
ASST Ovest Milanese
Lead Sponsor
Hippocrates Research
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Surgical procedure plus initial 2 days post-operative period
Participants undergo surgical removal or debridement of infected bone and soft tissues in the forefoot. Those in the Bioactive Glass group receive bone void filling with Bioactive Glass materials, while those in the Standard Care group receive standard surgical management without Bioactive Glass. Systemic antibiotic therapy starts immediately. A vacuum percutaneous drainage is placed before wound closure and removed by the second post-operative day if necessary.
Surgery day and post-operative day 2 visit (in-person)
Duration - Up to 3 months or until complete healing, then follow-up at 6 and 12 months
Participants are evaluated every two weeks to monitor wound healing, local conditions, and any complications such as non-healing or reinfection. Dressing changes and adverse events are recorded. Quality of life and foot function questionnaires are completed at pre-operative, 6 months, and 12 months visits. X-rays are performed pre-operation, immediate post-operation, and at 12 months.
Biweekly visits for up to 3 months, then visits at 6 months and 12 months (in-person)
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Fani Lalidou, George Kolios, Georgios I Drosos
https://pubmed.ncbi.nlm.nih.gov/24504740/Aslı Vatan, Nese Saltoglu, Mucahit Yemisen...
https://pubmed.ncbi.nlm.nih.gov/29381248/Alberto Piaggesi, Chiara Goretti, Elisabetta Iacopi...
https://pubmed.ncbi.nlm.nih.gov/27083507/N C Lindfors, P Hyvönen, M Nyyssönen...
https://pubmed.ncbi.nlm.nih.gov/20624692/Matti Peltola, Kalle Aitasalo, Jouko Suonpää...
https://pubmed.ncbi.nlm.nih.gov/16823870/Roberto De Giglio, Giacoma Di Vieste, Teresa Mondello...
https://pubmed.ncbi.nlm.nih.gov/33358382/Arlen D Hanssen
https://pubmed.ncbi.nlm.nih.gov/16056032/J McAndrew, C Efrimescu, E Sheehan...
https://pubmed.ncbi.nlm.nih.gov/23292733/Eveliina Munukka, Outi Leppäranta, Mika Korkeamäki...
https://pubmed.ncbi.nlm.nih.gov/17569007/Benjamin A Lipsky, Javier Aragón-Sánchez, Mathew Diggle...
https://pubmed.ncbi.nlm.nih.gov/26386266/ASST Ovest Milanese
Lead Sponsor
Hippocrates Research
Collaborating Sponsor